A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Moderna's latest CMO steps down after barely a year
Moderna's latest CMO steps down after barely a year
Moderna offloads late-stage rare disease drug to Recordati for $50M upfront
Moderna offloads late-stage rare disease drug to Recordati for $50M upfront
AstraZeneca returns to China's CSPC for $18.5B obesity deal
AstraZeneca returns to China's CSPC for $18.5B obesity deal
Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact
Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact
Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales
Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales
Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials
Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials
Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine
Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine
Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor
Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor
AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities
AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities
Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B
Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B
The new rules of biopharma M&A: 4 trends driving dealmaking this year
The new rules of biopharma M&A: 4 trends driving dealmaking this year
Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says
Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says
New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill
New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill
Eikon sets $274M goal for upcoming stock market debut
Eikon sets $274M goal for upcoming stock market debut
Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M
Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M
Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss
Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss
Medtech M&A 'rebounded' in 2025 as softer valuations drove deal competition: report
Medtech M&A 'rebounded' in 2025 as softer valuations drove deal competition: report
CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern'
CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern'
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page